Oncology & Critical Care

Bleomycin Injection (15 IU) is a cytotoxic glycopeptide antibiotic on the WHO Model List of Essential Medicines. It binds to intracellular ferrous iron (Fe2+) and molecular oxygen to form an activated pseudoperoxidase complex that cleaves single- and double-stranded DNA via free radical generation, arresting cells primarily in the G2 and M phases. Unlike most antineoplastics, it causes virtually no bone marrow suppression. Indicated for curative combination chemotherapy of testicular carcinoma (BEP regimen), Hodgkin lymphoma (ABVD regimen), non-Hodgkin lymphoma, and squamous cell carcinomas of the cervix and head and neck.

Cisplatin Injection (10mg/10ml, 50mg/50ml) is a first-generation platinum coordination complex antineoplastic agent on the WHO Model List of Essential Medicines. It forms intrastrand and interstrand crosslinks with DNA purine bases (predominantly guanine-guanine), distorting the DNA helix, halting replication and transcription, and triggering p53-dependent apoptotic cell death. Indicated for treatment of metastatic testicular cancer, advanced ovarian cancer, advanced bladder cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and cervical cancer.

Cisplatin Injection (10mg/10ml, 50mg/50ml) is a first-generation platinum coordination complex antineoplastic agent on the WHO Model List of Essential Medicines. It forms intrastrand and interstrand crosslinks with DNA purine bases (predominantly guanine-guanine), distorting the DNA helix, halting replication and transcription, and triggering p53-dependent apoptotic cell death. Indicated for treatment of metastatic testicular cancer, advanced ovarian cancer, advanced bladder cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and cervical cancer.

Doxorubicin Hydrochloride Injection (50mg / 2mg/ml) is a prototypical anthracycline cytotoxic antibiotic on the WHO Model List of Essential Medicines. It exerts anti-tumor effects through three mechanisms: DNA intercalation, topoisomerase II inhibition leading to double-strand DNA breaks, and generation of iron-mediated reactive oxygen free radicals that damage cell membranes and cellular organelles. Indicated for breast carcinoma, Hodgkin and non-Hodgkin lymphomas, acute lymphoblastic/myeloblastic leukemias, soft tissue sarcomas, osteosarcoma, and gastric cancer.

Etoposide Injection (100mg/5ml) and Capsules (50mg) is a semisynthetic podophyllotoxin derivative on the WHO Model List of Essential Medicines. It forms a ternary complex with DNA and topoisomerase II, preventing the re-ligation of cleaved DNA strands and causing permanent double-stranded breaks that arrest cells in late S and G2 phases. Indicated in combination chemotherapy for small cell lung cancer (SCLC), refractory testicular germ cell tumors, Hodgkin and non-Hodgkin lymphomas, and acute leukemias.

Gemcitabine Injection (200mg, 1000mg) is a difluoronucleoside pyrimidine antimetabolite on the WHO Model List of Essential Medicines. It is intracellularly phosphorylated to gemcitabine diphosphate (which inhibits ribonucleotide reductase, depleting deoxynucleotide pools) and gemcitabine triphosphate (which incorporates into replicating DNA, adding one additional nucleotide before DNA polymerases stall completely, masked from proofreading repair enzymes). Indicated for advanced pancreatic adenocarcinoma, non-small cell lung cancer (NSCLC), metastatic breast cancer, and advanced ovarian and bladder carcinomas.

Gemcitabine Injection (200mg, 1000mg) is a difluoronucleoside pyrimidine antimetabolite on the WHO Model List of Essential Medicines. It is intracellularly phosphorylated to gemcitabine diphosphate (which inhibits ribonucleotide reductase, depleting deoxynucleotide pools) and gemcitabine triphosphate (which incorporates into replicating DNA, adding one additional nucleotide before DNA polymerases stall completely, masked from proofreading repair enzymes). Indicated for advanced pancreatic adenocarcinoma, non-small cell lung cancer (NSCLC), metastatic breast cancer, and advanced ovarian and bladder carcinomas.

Tamoxifen Citrate Tablets (10mg, 20mg) is a selective estrogen receptor modulator (SERM) on the WHO Model List of Essential Medicines. In breast tissue, it competitively antagonizes estrogen binding to estrogen receptors (ER), halting ER-mediated transcription and arresting breast tumor cells in the G0/G1 phase. In bone and cardiovascular tissues, it acts as an estrogen agonist (preserving bone density and lipid profiles), but in the endometrium, its partial agonism stimulates endometrial proliferation. Indicated for adjuvant and metastatic treatment of estrogen receptor-positive (ER+) breast cancer in premenopausal and postmenopausal women, ductal carcinoma in situ (DCIS), and breast cancer chemoprevention in high-risk women.

Tamoxifen Citrate Tablets (10mg, 20mg) is a selective estrogen receptor modulator (SERM) on the WHO Model List of Essential Medicines. In breast tissue, it competitively antagonizes estrogen binding to estrogen receptors (ER), halting ER-mediated transcription and arresting breast tumor cells in the G0/G1 phase. In bone and cardiovascular tissues, it acts as an estrogen agonist (preserving bone density and lipid profiles), but in the endometrium, its partial agonism stimulates endometrial proliferation. Indicated for adjuvant and metastatic treatment of estrogen receptor-positive (ER+) breast cancer in premenopausal and postmenopausal women, ductal carcinoma in situ (DCIS), and breast cancer chemoprevention in high-risk women.

Trastuzumab Injection (440mg with WFI) is a recombinant humanized IgG1 monoclonal antibody on the WHO Model List of Essential Medicines that specifically targets the extracellular domain IV of the Human Epidermal Growth Factor Receptor 2 (HER2 / ErbB2) protein. It blocks ligand-independent HER2 homodimerization and downstream PI3K/Akt survival signaling, prevents shedding of the HER2 extracellular domain, and flags HER2-overexpressing tumor cells for Antibody-Dependent Cellular Cytotoxicity (ADCC) mediated by natural killer (NK) cells. Indicated for adjuvant and metastatic HER2-overexpressing (IHC 3+ or FISH-amplified) breast cancer and HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction.

Azathioprine Tablets (50 mg) is an oral imidazolyl derivative prodrug of 6-mercaptopurine (6-MP) on the WHO Model List of Essential Medicines. It is non-enzymatically cleaved by glutathione into 6-MP, which is intracellularly converted to 6-thioguanine nucleotides (6-TGN). 6-TGN incorporates into replicating DNA, causing chain termination, and inhibits de novo purine synthesis, suppressing clonal expansion of T- and B-lymphocytes. Indicated as an adjunct for prevention of rejection in renal allotransplantation and severe rheumatoid arthritis, lupus nephritis, Crohn's disease, ulcerative colitis, and autoimmune hepatitis.

Methotrexate Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg) is an oral antifolate antimetabolite and disease-modifying antirheumatic drug (DMARD) on the WHO Model List of Essential Medicines. It inhibits DHFR and suppresses inflammatory purine pathways, inhibiting AICAR transformylase and promoting extracellular adenosine release, which potently dampens immune cell activation. Indicated for rheumatoid arthritis, severe recalcitrant psoriasis, psoriatic arthritis, and maintenance therapy in acute lymphoblastic leukemia.

Megestrol Acetate Tablets (40mg) is a synthetic oral derivative of progesterone on the PMBI formulary. It downregulates luteinizing hormone secretion, exerts antiestrogenic activity in hormone-sensitive tumors, and centrally stimulates neuropeptide Y (NPY) and downregulates catabolic cytokines (TNF-alpha, IL-1, IL-6) in the hypothalamus, powerfully stimulating appetite and promoting non-fluid body weight gain. Indicated for treatment of anorexia, cachexia, and unexplained significant weight loss in patients with advanced cancer or AIDS, and palliative treatment of advanced endometrial and recurrent breast carcinoma.

Anastrozole Tablets (1mg) is a potent and selective non-steroidal third-generation aromatase inhibitor on the WHO Model List of Essential Medicines. It inhibits aromatase (CYP19A1) by competitive binding, suppressing serum estradiol concentrations by >80-85% in postmenopausal women without affecting cortisol, aldosterone, or thyroxine synthesis. Indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer and first-line treatment of locally advanced or metastatic HR+ breast cancer.

Bicalutamide Tablets (50mg) is an oral non-steroidal antiandrogen on the WHO Model List of Essential Medicines. It competitively antagonizes androgen binding to nuclear androgen receptors (AR) in the prostate gland and peripheral target tissues, preventing DHT-induced gene expression and cellular proliferation without displaying progestational or glucocorticoid agonist activity. Indicated in combination with a luteinizing hormone-releasing hormone (LHRH / GnRH) analogue for treatment of stage D2 metastatic prostate carcinoma (complete androgen blockade) and to prevent initial tumor flare upon LHRH agonist initiation.

Bortezomib Injection (2mg, 2.5mg, 3.5mg) is a dipeptidyl boronic acid reversible inhibitor of the 26S proteasome on the WHO Model List of Essential Medicines. It binds to the chymotrypsin-like catalytic site of the 20S core particle, preventing degradation of ubiquitinated proteins. This leads to toxic accumulation of intracellular polyubiquitinated proteins, stabilization of I-kappa-B-alpha, blockade of nuclear factor-kappa B (NF-kB) activation, and activation of the unfolded protein stress response, selectively killing multiple myeloma cells. Indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

Cyclosporine / Cyclosporin Capsules (25mg, 50mg, 100mg) is a cyclic polypeptide calcineurin inhibitor on the WHO Model List of Essential Medicines. Inside T-helper lymphocytes, it binds to the immunophilin cyclophilin; the resulting complex inhibits calcineurin phosphatase, preventing the dephosphorylation and nuclear translocation of nuclear factor of activated T-cells (NF-AT). This completely suppresses transcription of interleukin-2 (IL-2) and subsequent T-cell activation and proliferation. Indicated for prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants, and severe rheumatoid arthritis, psoriasis, and nephrotic syndrome.

Dacarbazine Injection (200mg) is an alkylating triazene antineoplastic on the WHO Model List of Essential Medicines. Following hepatic CYP1A bioactivation, it degrades to diazomethane and active 5-aminoimidazole-4-carboxamide (AIC), generating reactive methonium ions that alkylate DNA at O-6 and N-7 guanine positions. Indicated as a fundamental component of the ABVD regimen for Hodgkin lymphoma, metastatic malignant melanoma, and soft tissue sarcomas.

Daunorubicin Hydrochloride Injection (20mg) is an anthracycline antineoplastic antibiotic on the WHO Model List of Essential Medicines. It intercalates between DNA base pairs and inhibits topoisomerase II, producing cytotoxic double-strand DNA breaks. Indicated in combination with cytarabine ("7+3" induction regimen) for remission induction in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).

Imatinib Mesylate Tablets (400mg) is a revolutionary first-generation small-molecule protein tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It binds selectively to the ATP-binding pocket of the BCR-ABL chimeric tyrosine kinase (Philadelphia chromosome t(9;22)), locking it into an inactive conformation and terminating aberrant downstream proliferation signaling. Also potently inhibits receptor tyrosine kinases for platelet-derived growth factor (PDGFR) and stem cell factor (c-KIT / CD117). Indicated for newly diagnosed and chronic phase Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML), Ph+ Acute Lymphoblastic Leukemia (ALL), and c-KIT-positive Gastrointestinal Stromal Tumors (GIST).

Lenalidomide Capsules (5mg, 10mg, 25mg) is a potent second-generation 4-amino-glutamyl analogue immunomodulatory drug (IMiD) on the WHO Model List of Essential Medicines. It binds directly to cereblon (CRBN), the substrate recognition component of the cullin-RING E3 ubiquitin ligase complex CRL4-CRBN, inducing selective ubiquitination and proteasomal degradation of lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos). This causes direct multiple myeloma cell apoptosis, downregulates IRF4 and MYC, stimulates IL-2 production to activate NK and T-cells, and inhibits pro-angiogenic factors (VEGF, bFGF). Indicated in combination with dexamethasone for multiple myeloma, myelodysplastic syndrome (MDS) associated with deletion 5q, and relapsed mantle cell lymphoma.

Letrozole Tablets (2.5mg) is an oral non-steroidal third-generation aromatase inhibitor on the WHO Model List of Essential Medicines. It competitively binds to the heme group of the CYP19A1 aromatase enzyme, inhibiting the peripheral conversion of androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in adipose and peripheral tissues by >98.8%. In postmenopausal women, peripheral aromatization is the primary estrogen source. Indicated for adjuvant and first-line treatment of postmenopausal women with hormone receptor-positive (HR+) breast cancer, extended adjuvant therapy after 5 years of tamoxifen, and off-label ovulation induction in polycystic ovary syndrome (PCOS).

Leuprolide Acetate Depot Injection (3.75mg) is a synthetic nonapeptide gonadotropin-releasing hormone (GnRH / LHRH) superagonist on the WHO Model List of Essential Medicines. Following an initial transient surge in LH and FSH release (the "tumor flare" phenomenon lasting 1-2 weeks), continuous non-pulsatile administration profoundly downregulates pituitary GnRH receptors. Within 2 to 4 weeks, pituitary LH and FSH secretion is extinguished, suppressing testicular testosterone synthesis to surgical castration levels (<=50 ng/dL) in men and ovarian estradiol production to postmenopausal levels in women. Indicated for palliative treatment of advanced prostate cancer, central precocious puberty, endometriosis, and uterine leiomyomata (fibroids).

Mycophenolate Mofetil Tablets (500mg) and Mycophenolate Sodium Gastro-Resistant Tablets (360mg) is an oral prodrug of mycophenolic acid (MPA) on the WHO Model List of Essential Medicines. MPA is a potent, selective, non-competitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de novo guanine nucleotide synthesis. Because T- and B-lymphocytes rely almost exclusively on the de novo pathway for purine generation (unlike other cell types that utilize the salvage pathway), mycophenolate selectively blocks lymphocyte proliferation and antibody production. Indicated in combination with cyclosporine/tacrolimus and corticosteroids for prophylaxis of organ rejection in kidney, heart, and liver allografts, and for induction and maintenance of lupus nephritis.

Oxaliplatin Injection (50mg) is a third-generation diaminocyclohexane (DACH) platinum antineoplastic on the WHO Model List of Essential Medicines. The bulky DACH ring forms platinum-DNA adducts that circumvent standard mismatch repair mechanisms and overcome cross-resistance to cisplatin and carboplatin. Indicated in combination with infusional 5-FU/leucovorin (FOLFOX regimen) for adjuvant treatment of stage III colon cancer, metastatic colorectal cancer, and pancreatic adenocarcinoma.

Paclitaxel Injection (100mg / 6mg/ml) is a plant alkaloid taxane antineoplastic on the WHO Model List of Essential Medicines. It binds with high affinity to the beta-tubulin subunit of microtubules, promoting microtubule assembly and preventing microtubule depolymerization. This stabilizes the microtubule polymer network, freezing the mitotic spindle apparatus and blocking cell cycle progression at the metaphase/anaphase transition, inducing apoptosis. Indicated for advanced ovarian carcinoma, node-positive breast cancer, metastatic non-small cell lung cancer, and AIDS-related Kaposi sarcoma.

5-Fluorouracil (5-FU) Injection (500mg) is a fluorinated pyrimidine antimetabolite on the WHO Model List of Essential Medicines. It is intracellularly converted to 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which forms a stable ternary complex with thymidylate synthase (TS) and 5,10-methylenetetrahydrofolate (potentiated by leucovorin), blocking thymidylate and DNA synthesis. Indicated for colorectal carcinoma, breast cancer, gastric cancer, pancreatic adenocarcinoma, and head and neck cancers.

Carboplatin Injection (150mg, 450mg) is a second-generation platinum antineoplastic agent on the WHO Model List of Essential Medicines. It incorporates a bidentate cyclobutanedicarboxylate leaving group that slows activation kinetics, producing DNA crosslinks similar to cisplatin but with dramatically reduced nephrotoxicity, ototoxicity, and emetogenicity. Dosing is individualized using the Calvert formula: Total Dose (mg) = Target AUC × (GFR + 25). Indicated for initial and palliative chemotherapy of advanced ovarian carcinoma, small cell lung cancer, non-small cell lung cancer, and head and neck neoplasms.

Carboplatin Injection (150mg, 450mg) is a second-generation platinum antineoplastic agent on the WHO Model List of Essential Medicines. It incorporates a bidentate cyclobutanedicarboxylate leaving group that slows activation kinetics, producing DNA crosslinks similar to cisplatin but with dramatically reduced nephrotoxicity, ototoxicity, and emetogenicity. Dosing is individualized using the Calvert formula: Total Dose (mg) = Target AUC × (GFR + 25). Indicated for initial and palliative chemotherapy of advanced ovarian carcinoma, small cell lung cancer, non-small cell lung cancer, and head and neck neoplasms.

Cyclophosphamide Injection (500mg) is an oxazaphosphorine nitrogen mustard alkylating prodrug on the WHO Model List of Essential Medicines. In the liver, CYP2B6 oxidizes it to 4-hydroxycyclophosphamide, which spontaneously decomposes into phosphoramide mustard (the active alkylating moiety that forms crosslinks at guanine N-7 positions in DNA) and acrolein (a toxic metabolite excreted in urine). Indicated for non-Hodgkin and Hodgkin lymphomas, acute and chronic leukemias, breast cancer, ovarian cancer, neuroblastoma, and severe autoimmune diseases (lupus nephritis).

Cyclosporine / Cyclosporin Capsules (25mg, 50mg, 100mg) is a cyclic polypeptide calcineurin inhibitor on the WHO Model List of Essential Medicines. Inside T-helper lymphocytes, it binds to the immunophilin cyclophilin; the resulting complex inhibits calcineurin phosphatase, preventing the dephosphorylation and nuclear translocation of nuclear factor of activated T-cells (NF-AT). This completely suppresses transcription of interleukin-2 (IL-2) and subsequent T-cell activation and proliferation. Indicated for prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants, and severe rheumatoid arthritis, psoriasis, and nephrotic syndrome.

Cyclosporine / Cyclosporin Capsules (25mg, 50mg, 100mg) is a cyclic polypeptide calcineurin inhibitor on the WHO Model List of Essential Medicines. Inside T-helper lymphocytes, it binds to the immunophilin cyclophilin; the resulting complex inhibits calcineurin phosphatase, preventing the dephosphorylation and nuclear translocation of nuclear factor of activated T-cells (NF-AT). This completely suppresses transcription of interleukin-2 (IL-2) and subsequent T-cell activation and proliferation. Indicated for prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants, and severe rheumatoid arthritis, psoriasis, and nephrotic syndrome.

Hydroxyurea / Hydroxycarbamide Capsules (500mg) is an oral ribonucleotide reductase inhibitor on the WHO Model List of Essential Medicines. It selectively inactivates the tyrosyl free radical of the M2 subunit of ribonucleotide reductase, blocking conversion of ribonucleotides to deoxyribonucleotides and inhibiting DNA synthesis without interfering with RNA or protein synthesis. In sickle cell disease, it stimulates fetal hemoglobin (HbF) synthesis. Indicated for chronic myeloid leukemia (CML) in blast phase/cytoreduction, polycythemia vera, essential thrombocythemia, and sickle cell anemia.

Ifosfamide Injection (1gm) is an oxazaphosphorine alkylating agent related to cyclophosphamide on the WHO Model List of Essential Medicines. It requires hepatic CYP3A4 bioactivation to ifosforamide mustard, which crosslinks DNA strands, and produces substantial quantities of toxic acrolein and chloroacetaldehyde. Indicated in combination with other antineoplastics for testicular cancer, soft tissue and bone sarcomas (Ewing sarcoma, osteosarcoma), non-Hodgkin lymphoma, and small cell lung cancer.

Docetaxel Injection (80mg, 120mg) is a semi-synthetic taxane antineoplastic on the WHO Model List of Essential Medicines. It binds to free tubulin and stabilizes microtubule bundles, inhibiting mitotic spindle dissolution with approximately double the tubulin-binding affinity of paclitaxel. Indicated for locally advanced or metastatic breast cancer, non-small cell lung cancer, hormone-refractory metastatic prostate cancer (with prednisone), gastric adenocarcinoma, and squamous cell carcinoma of the head and neck.

Docetaxel Injection (80mg, 120mg) is a semi-synthetic taxane antineoplastic on the WHO Model List of Essential Medicines. It binds to free tubulin and stabilizes microtubule bundles, inhibiting mitotic spindle dissolution with approximately double the tubulin-binding affinity of paclitaxel. Indicated for locally advanced or metastatic breast cancer, non-small cell lung cancer, hormone-refractory metastatic prostate cancer (with prednisone), gastric adenocarcinoma, and squamous cell carcinoma of the head and neck.

Erlotinib Tablets (150mg) is an oral first-generation epidermal growth factor receptor (EGFR / HER1) tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It reversibly competes with ATP for binding to the intracellular kinase domain of EGFR harboring activating mutations (exon 19 in-frame deletions or exon 21 L858R point mutations), blocking autophosphorylation and downstream pro-survival RAS/RAF/MAPK signaling. Indicated for first-line and maintenance therapy of metastatic non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations, and in combination with gemcitabine for locally advanced, unresectable pancreatic cancer.

Gefitinib Tablets (250mg) is an oral selective first-generation EGFR tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It competitively inhibits ATP binding at the tyrosine kinase catalytic domain of mutated EGFR (exon 19 deletion or exon 21 L858R substitution), arresting cell cycle progression and stimulating apoptosis in EGFR-addicted tumor cells. Indicated for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have sensitizing EGFR mutations.

Pemetrexed Injection (100mg, 500mg) is a pyrrolopyrimidine-based multi-targeted antifolate antineoplastic on the WHO Model List of Essential Medicines. It simultaneously inhibits three key enzymes required for purine and pyrimidine biosynthesis: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). Indicated in combination with cisplatin (and as maintenance monotherapy) for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.

Pemetrexed Injection (100mg, 500mg) is a pyrrolopyrimidine-based multi-targeted antifolate antineoplastic on the WHO Model List of Essential Medicines. It simultaneously inhibits three key enzymes required for purine and pyrimidine biosynthesis: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). Indicated in combination with cisplatin (and as maintenance monotherapy) for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma.

Temozolomide Capsules (20mg, 100mg, 250mg) is an oral imidazotetrazine alkylating prodrug on the WHO Model List of Essential Medicines. Unlike dacarbazine, it does not require hepatic enzymatic activation; at physiological systemic pH (7.4), it undergoes spontaneous non-enzymatic conversion to active MTIC, which methylates DNA at the O-6 and N-7 positions of guanine. O-6 methylguanine mispairs with thymine during replication, triggering repetitive futile mismatch repair cycles that culminate in lethal double-strand DNA breaks. Excellent blood-brain barrier penetration. Indicated for newly diagnosed Glioblastoma Multiforme (concomitant with radiotherapy and adjuvant maintenance, the Stupp protocol) and refractory anaplastic astrocytoma.

Temozolomide Capsules (20mg, 100mg, 250mg) is an oral imidazotetrazine alkylating prodrug on the WHO Model List of Essential Medicines. Unlike dacarbazine, it does not require hepatic enzymatic activation; at physiological systemic pH (7.4), it undergoes spontaneous non-enzymatic conversion to active MTIC, which methylates DNA at the O-6 and N-7 positions of guanine. O-6 methylguanine mispairs with thymine during replication, triggering repetitive futile mismatch repair cycles that culminate in lethal double-strand DNA breaks. Excellent blood-brain barrier penetration. Indicated for newly diagnosed Glioblastoma Multiforme (concomitant with radiotherapy and adjuvant maintenance, the Stupp protocol) and refractory anaplastic astrocytoma.

Capecitabine Tablets (500mg) is an orally administered fluoropyrimidine carbamate prodrug on the WHO Model List of Essential Medicines. It undergoes three-step sequential enzymatic activation: hepatic carboxylesterase hydrolyzes it to 5'-DFCR, cytidine deaminase converts it to 5'-DFUR, and thymidine phosphorylase (which is expressed at significantly higher concentrations in tumor tissues compared to normal tissues) converts it to active 5-FU. This tumor-selective activation delivers high intratumoral fluorouracil concentrations while minimizing systemic toxicity. Indicated for adjuvant and metastatic colorectal cancer, metastatic breast cancer resistant to anthracyclines and taxanes, and advanced gastric cancer.

Etoposide Injection (100mg/5ml) and Capsules (50mg) is a semisynthetic podophyllotoxin derivative on the WHO Model List of Essential Medicines. It forms a ternary complex with DNA and topoisomerase II, preventing the re-ligation of cleaved DNA strands and causing permanent double-stranded breaks that arrest cells in late S and G2 phases. Indicated in combination chemotherapy for small cell lung cancer (SCLC), refractory testicular germ cell tumors, Hodgkin and non-Hodgkin lymphomas, and acute leukemias.

Tacrolimus Capsules (0.25mg, 1mg, 2mg) is a potent macrolide calcineurin inhibitor on the WHO Model List of Essential Medicines. It binds to intracellular FK506-binding protein-12 (FKBP-12); the drug-protein complex binds and inhibits calcineurin phosphatase with 10- to 100-fold higher potency than cyclosporine, extinguishing IL-2 gene transcription, T-cell proliferation, and cytotoxic lymphocyte generation. Indicated for prophylaxis of organ rejection in patients receiving allogeneic kidney, liver, or heart transplants, and rescue therapy in refractory rejection.

Tacrolimus Capsules (0.25mg, 1mg, 2mg) is a potent macrolide calcineurin inhibitor on the WHO Model List of Essential Medicines. It binds to intracellular FK506-binding protein-12 (FKBP-12); the drug-protein complex binds and inhibits calcineurin phosphatase with 10- to 100-fold higher potency than cyclosporine, extinguishing IL-2 gene transcription, T-cell proliferation, and cytotoxic lymphocyte generation. Indicated for prophylaxis of organ rejection in patients receiving allogeneic kidney, liver, or heart transplants, and rescue therapy in refractory rejection.

Tacrolimus Capsules (0.25mg, 1mg, 2mg) is a potent macrolide calcineurin inhibitor on the WHO Model List of Essential Medicines. It binds to intracellular FK506-binding protein-12 (FKBP-12); the drug-protein complex binds and inhibits calcineurin phosphatase with 10- to 100-fold higher potency than cyclosporine, extinguishing IL-2 gene transcription, T-cell proliferation, and cytotoxic lymphocyte generation. Indicated for prophylaxis of organ rejection in patients receiving allogeneic kidney, liver, or heart transplants, and rescue therapy in refractory rejection.

Methotrexate Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg) is an oral antifolate antimetabolite and disease-modifying antirheumatic drug (DMARD) on the WHO Model List of Essential Medicines. It inhibits DHFR and suppresses inflammatory purine pathways, inhibiting AICAR transformylase and promoting extracellular adenosine release, which potently dampens immune cell activation. Indicated for rheumatoid arthritis, severe recalcitrant psoriasis, psoriatic arthritis, and maintenance therapy in acute lymphoblastic leukemia.

Methotrexate Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg) is an oral antifolate antimetabolite and disease-modifying antirheumatic drug (DMARD) on the WHO Model List of Essential Medicines. It inhibits DHFR and suppresses inflammatory purine pathways, inhibiting AICAR transformylase and promoting extracellular adenosine release, which potently dampens immune cell activation. Indicated for rheumatoid arthritis, severe recalcitrant psoriasis, psoriatic arthritis, and maintenance therapy in acute lymphoblastic leukemia.

Methotrexate Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg) is an oral antifolate antimetabolite and disease-modifying antirheumatic drug (DMARD) on the WHO Model List of Essential Medicines. It inhibits DHFR and suppresses inflammatory purine pathways, inhibiting AICAR transformylase and promoting extracellular adenosine release, which potently dampens immune cell activation. Indicated for rheumatoid arthritis, severe recalcitrant psoriasis, psoriatic arthritis, and maintenance therapy in acute lymphoblastic leukemia.

Mycophenolate Mofetil Tablets (500mg) and Mycophenolate Sodium Gastro-Resistant Tablets (360mg) is an oral prodrug of mycophenolic acid (MPA) on the WHO Model List of Essential Medicines. MPA is a potent, selective, non-competitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in de novo guanine nucleotide synthesis. Because T- and B-lymphocytes rely almost exclusively on the de novo pathway for purine generation (unlike other cell types that utilize the salvage pathway), mycophenolate selectively blocks lymphocyte proliferation and antibody production. Indicated in combination with cyclosporine/tacrolimus and corticosteroids for prophylaxis of organ rejection in kidney, heart, and liver allografts, and for induction and maintenance of lupus nephritis.

Rituximab Injection (100mg/10ml, 500mg/50ml) is a genetically engineered chimeric murine/human IgG1-kappa monoclonal antibody on the WHO Model List of Essential Medicines targeting the transmembrane CD20 antigen expressed on pre-B and mature B lymphocytes. Binding of rituximab to CD20 triggers complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct structural apoptosis, rapidly clearing normal and malignant B-cells from circulation. Indicated for Non-Hodgkin Lymphoma (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis refractory to anti-TNF agents, Granulomatosis with Polyangiitis (Wegener's), and Pemphigus Vulgaris.

Rituximab Injection (100mg/10ml, 500mg/50ml) is a genetically engineered chimeric murine/human IgG1-kappa monoclonal antibody on the WHO Model List of Essential Medicines targeting the transmembrane CD20 antigen expressed on pre-B and mature B lymphocytes. Binding of rituximab to CD20 triggers complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct structural apoptosis, rapidly clearing normal and malignant B-cells from circulation. Indicated for Non-Hodgkin Lymphoma (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis refractory to anti-TNF agents, Granulomatosis with Polyangiitis (Wegener's), and Pemphigus Vulgaris.

Abiraterone Acetate Tablets (250mg, 500mg) is an oral prodrug inhibitor of androgen biosynthesis on the WHO Model List of Essential Medicines. It is converted to abiraterone, which selectively and irreversibly inhibits the 17-alpha-hydroxylase and C17,20-lyase activities of the CYP17A1 enzyme in testicular, adrenal, and intratumoral prostate cancer tissues. This shuts down androgen synthesis across all three sources, depriving androgen-dependent prostate cancer cells of testosterone and DHT. Because CYP17 inhibition blocks cortisol production, secondary ACTH elevation triggers mineralocorticoid excess (hypertension, hypokalemia, edema); therefore, abiraterone MUST ALWAYS be co-administered with oral prednisone. Indicated in combination with prednisone for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).

Dasatinib Tablets (20mg, 50mg, 70mg) is a second-generation dual BCR-ABL and SRC family tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It binds to both the active and inactive conformations of the BCR-ABL kinase domain with >300-fold higher potency than imatinib, overcoming most imatinib-resistant BCR-ABL kinase domain mutations (except the gatekeeper T315I mutation). Indicated for newly diagnosed Ph+ CML in chronic phase, and accelerated/blast phase CML or Ph+ ALL with resistance or intolerance to prior therapy including imatinib.

Lapatinib Tablets (250mg) is an oral dual tyrosine kinase inhibitor of both EGFR (ErbB1) and HER2/neu (ErbB2) on the PMBI formulary. It reversibly binds to the intracellular ATP-binding domain of both receptors, inhibiting receptor phosphorylation and shutting down downstream MAPK and PI3K/Akt survival cascades in HER2-overexpressing tumor cells. Able to cross the blood-brain barrier. Indicated in combination with capecitabine for advanced or metastatic HER2-positive breast cancer progressing after prior trastuzumab, anthracyclines, and taxanes, and with letrozole for hormone receptor-positive/HER2-positive breast cancer.

Nintedanib Soft Gelatin Capsules (100mg, 150mg) is an oral triple angiokinase inhibitor that targets receptor tyrosine kinases for vascular endothelial growth factor (VEGFR-1/2/3), fibroblast growth factor (FGFR-1/2/3), and platelet-derived growth factor (PDGFR-alpha/beta). In pulmonary fibrosis, it inhibits proliferation, migration, and transformation of lung fibroblasts into myofibroblasts, slowing the rate of pulmonary function decline (FVC loss). Indicated for Idiopathic Pulmonary Fibrosis (IPF), chronic fibrosing interstitial lung diseases with a progressive phenotype, systemic sclerosis-associated ILD, and in combination with docetaxel for advanced NSCLC of adenocarcinoma histology.

Pomalidomide Capsules (2mg) is a third-generation, highly potent immunomodulatory agent (IMiD) on the WHO Model List framework. It binds to cereblon with >10-fold higher affinity than lenalidomide, recruiting and degrading IKZF1/IKZF3 even in lenalidomide-refractory multiple myeloma clones, triggering enhanced myeloma apoptosis and T-cell co-stimulation. Indicated in combination with low-dose dexamethasone for patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

Bortezomib Injection (2mg, 2.5mg, 3.5mg) is a dipeptidyl boronic acid reversible inhibitor of the 26S proteasome on the WHO Model List of Essential Medicines. It binds to the chymotrypsin-like catalytic site of the 20S core particle, preventing degradation of ubiquitinated proteins. This leads to toxic accumulation of intracellular polyubiquitinated proteins, stabilization of I-kappa-B-alpha, blockade of nuclear factor-kappa B (NF-kB) activation, and activation of the unfolded protein stress response, selectively killing multiple myeloma cells. Indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

Bortezomib Injection (2mg, 2.5mg, 3.5mg) is a dipeptidyl boronic acid reversible inhibitor of the 26S proteasome on the WHO Model List of Essential Medicines. It binds to the chymotrypsin-like catalytic site of the 20S core particle, preventing degradation of ubiquitinated proteins. This leads to toxic accumulation of intracellular polyubiquitinated proteins, stabilization of I-kappa-B-alpha, blockade of nuclear factor-kappa B (NF-kB) activation, and activation of the unfolded protein stress response, selectively killing multiple myeloma cells. Indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.

Crizotinib Capsules (250mg) is an oral small-molecule receptor tyrosine kinase inhibitor targeting Anaplastic Lymphoma Kinase (ALK), ROS1, and hepatocyte growth factor receptor (HGFR / c-MET) on the WHO Model List framework. It selectively inhibits ATP binding to the chimeric EML4-ALK fusion kinase or ROS1 fusion protein, halting aberrant downstream signaling. Indicated for locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive or ROS1-positive as detected by an approved test.

Dasatinib Tablets (20mg, 50mg, 70mg) is a second-generation dual BCR-ABL and SRC family tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It binds to both the active and inactive conformations of the BCR-ABL kinase domain with >300-fold higher potency than imatinib, overcoming most imatinib-resistant BCR-ABL kinase domain mutations (except the gatekeeper T315I mutation). Indicated for newly diagnosed Ph+ CML in chronic phase, and accelerated/blast phase CML or Ph+ ALL with resistance or intolerance to prior therapy including imatinib.

Dasatinib Tablets (20mg, 50mg, 70mg) is a second-generation dual BCR-ABL and SRC family tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It binds to both the active and inactive conformations of the BCR-ABL kinase domain with >300-fold higher potency than imatinib, overcoming most imatinib-resistant BCR-ABL kinase domain mutations (except the gatekeeper T315I mutation). Indicated for newly diagnosed Ph+ CML in chronic phase, and accelerated/blast phase CML or Ph+ ALL with resistance or intolerance to prior therapy including imatinib.

Dasatinib Tablets (20mg, 50mg, 70mg) is a second-generation dual BCR-ABL and SRC family tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It binds to both the active and inactive conformations of the BCR-ABL kinase domain with >300-fold higher potency than imatinib, overcoming most imatinib-resistant BCR-ABL kinase domain mutations (except the gatekeeper T315I mutation). Indicated for newly diagnosed Ph+ CML in chronic phase, and accelerated/blast phase CML or Ph+ ALL with resistance or intolerance to prior therapy including imatinib.

Eltrombopag Tablets (25mg, 50mg) is an oral, non-peptide thrombopoietin (TPO) receptor agonist on the WHO Model List of Essential Medicines. It interacts with the transmembrane domain of the human TPO receptor (c-Mpl) on megakaryocytes and hematopoietic stem cells, initiating JAK/STAT and MAPK signaling pathways that stimulate megakaryocyte proliferation and differentiation, elevating platelet counts. Indicated for chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to corticosteroids or immunoglobulins, severe aplastic anemia, and thrombocytopenia in patients with chronic hepatitis C to allow interferon therapy.

Eltrombopag Tablets (25mg, 50mg) is an oral, non-peptide thrombopoietin (TPO) receptor agonist on the WHO Model List of Essential Medicines. It interacts with the transmembrane domain of the human TPO receptor (c-Mpl) on megakaryocytes and hematopoietic stem cells, initiating JAK/STAT and MAPK signaling pathways that stimulate megakaryocyte proliferation and differentiation, elevating platelet counts. Indicated for chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to corticosteroids or immunoglobulins, severe aplastic anemia, and thrombocytopenia in patients with chronic hepatitis C to allow interferon therapy.

Lenalidomide Capsules (5mg, 10mg, 25mg) is a potent second-generation 4-amino-glutamyl analogue immunomodulatory drug (IMiD) on the WHO Model List of Essential Medicines. It binds directly to cereblon (CRBN), the substrate recognition component of the cullin-RING E3 ubiquitin ligase complex CRL4-CRBN, inducing selective ubiquitination and proteasomal degradation of lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos). This causes direct multiple myeloma cell apoptosis, downregulates IRF4 and MYC, stimulates IL-2 production to activate NK and T-cells, and inhibits pro-angiogenic factors (VEGF, bFGF). Indicated in combination with dexamethasone for multiple myeloma, myelodysplastic syndrome (MDS) associated with deletion 5q, and relapsed mantle cell lymphoma.

Lenalidomide Capsules (5mg, 10mg, 25mg) is a potent second-generation 4-amino-glutamyl analogue immunomodulatory drug (IMiD) on the WHO Model List of Essential Medicines. It binds directly to cereblon (CRBN), the substrate recognition component of the cullin-RING E3 ubiquitin ligase complex CRL4-CRBN, inducing selective ubiquitination and proteasomal degradation of lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos). This causes direct multiple myeloma cell apoptosis, downregulates IRF4 and MYC, stimulates IL-2 production to activate NK and T-cells, and inhibits pro-angiogenic factors (VEGF, bFGF). Indicated in combination with dexamethasone for multiple myeloma, myelodysplastic syndrome (MDS) associated with deletion 5q, and relapsed mantle cell lymphoma.

Methotrexate Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg) is an oral antifolate antimetabolite and disease-modifying antirheumatic drug (DMARD) on the WHO Model List of Essential Medicines. It inhibits DHFR and suppresses inflammatory purine pathways, inhibiting AICAR transformylase and promoting extracellular adenosine release, which potently dampens immune cell activation. Indicated for rheumatoid arthritis, severe recalcitrant psoriasis, psoriatic arthritis, and maintenance therapy in acute lymphoblastic leukemia.

Methotrexate Tablets (2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg) is an oral antifolate antimetabolite and disease-modifying antirheumatic drug (DMARD) on the WHO Model List of Essential Medicines. It inhibits DHFR and suppresses inflammatory purine pathways, inhibiting AICAR transformylase and promoting extracellular adenosine release, which potently dampens immune cell activation. Indicated for rheumatoid arthritis, severe recalcitrant psoriasis, psoriatic arthritis, and maintenance therapy in acute lymphoblastic leukemia.

Nintedanib Soft Gelatin Capsules (100mg, 150mg) is an oral triple angiokinase inhibitor that targets receptor tyrosine kinases for vascular endothelial growth factor (VEGFR-1/2/3), fibroblast growth factor (FGFR-1/2/3), and platelet-derived growth factor (PDGFR-alpha/beta). In pulmonary fibrosis, it inhibits proliferation, migration, and transformation of lung fibroblasts into myofibroblasts, slowing the rate of pulmonary function decline (FVC loss). Indicated for Idiopathic Pulmonary Fibrosis (IPF), chronic fibrosing interstitial lung diseases with a progressive phenotype, systemic sclerosis-associated ILD, and in combination with docetaxel for advanced NSCLC of adenocarcinoma histology.

Pazopanib Tablets (200mg, 400mg) is an oral second-generation multi-tyrosine kinase inhibitor on the WHO Model List framework. It potently inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, PDGFR-beta, and c-KIT, starving tumors of blood supply. Indicated for advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.

Pazopanib Tablets (200mg, 400mg) is an oral second-generation multi-tyrosine kinase inhibitor on the WHO Model List framework. It potently inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, PDGFR-beta, and c-KIT, starving tumors of blood supply. Indicated for advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS) in patients who have received prior chemotherapy.

Sorafenib Tablets (200mg) is an oral multi-kinase inhibitor targeting both tumor cell proliferation and tumor angiogenesis on the WHO Model List of Essential Medicines. It potently inhibits intracellular serine/threonine kinases in the RAF/MEK/ERK pathway (CRAF, BRAF, mutant V600E BRAF) and cell-surface receptor tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-beta, FLT3, and RET. Indicated for unresectable hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and locally recurrent or metastatic progressive radioactive iodine-refractory differentiated thyroid carcinoma.

Sunitinib Capsules (12.5mg, 25mg) is an oral multi-targeted receptor tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It blocks signaling by VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, PDGFR-beta, c-KIT, FLT3, and RET, exerting powerful anti-angiogenic and direct antiproliferative effects. Indicated for advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib, and progressive neuroendocrine tumors of pancreatic origin (pNET).

Sunitinib Capsules (12.5mg, 25mg) is an oral multi-targeted receptor tyrosine kinase inhibitor on the WHO Model List of Essential Medicines. It blocks signaling by VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, PDGFR-beta, c-KIT, FLT3, and RET, exerting powerful anti-angiogenic and direct antiproliferative effects. Indicated for advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib, and progressive neuroendocrine tumors of pancreatic origin (pNET).

Temozolomide Capsules (20mg, 100mg, 250mg) is an oral imidazotetrazine alkylating prodrug on the WHO Model List of Essential Medicines. Unlike dacarbazine, it does not require hepatic enzymatic activation; at physiological systemic pH (7.4), it undergoes spontaneous non-enzymatic conversion to active MTIC, which methylates DNA at the O-6 and N-7 positions of guanine. O-6 methylguanine mispairs with thymine during replication, triggering repetitive futile mismatch repair cycles that culminate in lethal double-strand DNA breaks. Excellent blood-brain barrier penetration. Indicated for newly diagnosed Glioblastoma Multiforme (concomitant with radiotherapy and adjuvant maintenance, the Stupp protocol) and refractory anaplastic astrocytoma.

Thalidomide Capsules (50mg, 100mg, 200mg) is the prototypical immunomodulatory drug (IMiD) on the WHO Model List of Essential Medicines. It binds to cereblon (CRBN), promoting degradation of IKZF1 and IKZF3, and suppresses tumor necrosis factor-alpha (TNF-alpha) synthesis while inhibiting basic fibroblast growth factor (bFGF) and VEGF-induced angiogenesis. Indicated in combination with dexamethasone for newly diagnosed multiple myeloma and for acute treatment and maintenance of erythema nodosum leprosum (ENL / Hansen's disease).

Thalidomide Capsules (50mg, 100mg, 200mg) is the prototypical immunomodulatory drug (IMiD) on the WHO Model List of Essential Medicines. It binds to cereblon (CRBN), promoting degradation of IKZF1 and IKZF3, and suppresses tumor necrosis factor-alpha (TNF-alpha) synthesis while inhibiting basic fibroblast growth factor (bFGF) and VEGF-induced angiogenesis. Indicated in combination with dexamethasone for newly diagnosed multiple myeloma and for acute treatment and maintenance of erythema nodosum leprosum (ENL / Hansen's disease).

Thalidomide Capsules (50mg, 100mg, 200mg) is the prototypical immunomodulatory drug (IMiD) on the WHO Model List of Essential Medicines. It binds to cereblon (CRBN), promoting degradation of IKZF1 and IKZF3, and suppresses tumor necrosis factor-alpha (TNF-alpha) synthesis while inhibiting basic fibroblast growth factor (bFGF) and VEGF-induced angiogenesis. Indicated in combination with dexamethasone for newly diagnosed multiple myeloma and for acute treatment and maintenance of erythema nodosum leprosum (ENL / Hansen's disease).

Leucovorin Calcium / Folinic Acid Tablets (15mg) is the 5-formyl derivative of tetrahydrofolic acid (FH4) on the WHO Model List of Essential Medicines. It bypasses the enzymatic block created by dihydrofolate reductase (DHFR) inhibitors (such as methotrexate), directly entering folate cofactor pools to rescue normal host tissues from lethal toxicity ("Leucovorin Rescue"). Concurrently, in 5-fluorouracil chemotherapy, leucovorin stabilizes the ternary binding complex with thymidylate synthase, markedly enhancing 5-FU cytotoxicity. Indicated for rescue therapy following high-dose methotrexate chemotherapy, accidental methotrexate overdose, and potentiation of 5-FU in metastatic colorectal carcinoma.

Methotrexate Injection (25mg/ml, 50mg/2ml) is an antifolate antimetabolite on the WHO Model List of Essential Medicines. It competitively and irreversibly inhibits dihydrofolate reductase (DHFR), halting the conversion of dihydrofolate to tetrahydrofolate (FH4) and blocking de novo synthesis of thymidylate and purine nucleotides essential for DNA and RNA synthesis. Indicated for acute lymphoblastic leukemia (ALL), osteosarcoma, choriocarcinoma, breast cancer, head and neck carcinomas, non-Hodgkin lymphoma, and severe recalcitrant psoriasis/rheumatoid arthritis.

Methotrexate Injection (25mg/ml, 50mg/2ml) is an antifolate antimetabolite on the WHO Model List of Essential Medicines. It competitively and irreversibly inhibits dihydrofolate reductase (DHFR), halting the conversion of dihydrofolate to tetrahydrofolate (FH4) and blocking de novo synthesis of thymidylate and purine nucleotides essential for DNA and RNA synthesis. Indicated for acute lymphoblastic leukemia (ALL), osteosarcoma, choriocarcinoma, breast cancer, head and neck carcinomas, non-Hodgkin lymphoma, and severe recalcitrant psoriasis/rheumatoid arthritis.

Panitumumab Infusion (100mg, 400mg) is a recombinant, fully human IgG2 monoclonal antibody on the WHO Model List of Essential Medicines that binds specifically to the human Epidermal Growth Factor Receptor (EGFR / HER1). It competitively prevents binding of endogenous EGF and TGF-alpha, halting EGFR dimerization, receptor autophosphorylation, and downstream pro-proliferative intracellular cascades. Indicated for wild-type KRAS and NRAS (exon 2, 3, and 4) metastatic colorectal carcinoma (mCRC), as first-line therapy with FOLFOX, or as monotherapy following progression on oxaliplatin, irinotecan, and fluoropyrimidines.

Panitumumab Infusion (100mg, 400mg) is a recombinant, fully human IgG2 monoclonal antibody on the WHO Model List of Essential Medicines that binds specifically to the human Epidermal Growth Factor Receptor (EGFR / HER1). It competitively prevents binding of endogenous EGF and TGF-alpha, halting EGFR dimerization, receptor autophosphorylation, and downstream pro-proliferative intracellular cascades. Indicated for wild-type KRAS and NRAS (exon 2, 3, and 4) metastatic colorectal carcinoma (mCRC), as first-line therapy with FOLFOX, or as monotherapy following progression on oxaliplatin, irinotecan, and fluoropyrimidines.

Sirolimus / Rapamycin Tablets (1mg) is a macrocyclic lactone immunosuppressive agent on the WHO Model List framework. It binds intracellularly to immunophilin FKBP-12, but unlike tacrolimus, the sirolimus-FKBP-12 complex binds to and inhibits the mammalian target of rapamycin (mTOR) kinase complex 1 (mTORC1). This blocks IL-2-stimulated progression from G1 to S phase in T-lymphocytes. Completely non-nephrotoxic compared to calcineurin inhibitors. Indicated for prophylaxis of organ rejection in kidney transplant recipients (often to spare calcineurin inhibitor nephrotoxicity) and treatment of lymphangioleiomyomatosis (LAM).

Cabozantinib Tablets (20mg, 40mg, 60mg) is an oral multi-tyrosine kinase inhibitor targeting MET, VEGFR-1/2/3, RET, AXL, KIT, and TIE-2 on the PMBI formulary. Simultaneous inhibition of MET and AXL overcomes resistance pathways commonly triggered by VEGF-only blockade. Indicated for advanced renal cell carcinoma (RCC) following prior anti-angiogenic therapy, hepatocellular carcinoma (HCC) previously treated with sorafenib, and progressive medullary thyroid cancer.

Cabozantinib Tablets (20mg, 40mg, 60mg) is an oral multi-tyrosine kinase inhibitor targeting MET, VEGFR-1/2/3, RET, AXL, KIT, and TIE-2 on the PMBI formulary. Simultaneous inhibition of MET and AXL overcomes resistance pathways commonly triggered by VEGF-only blockade. Indicated for advanced renal cell carcinoma (RCC) following prior anti-angiogenic therapy, hepatocellular carcinoma (HCC) previously treated with sorafenib, and progressive medullary thyroid cancer.

Cabozantinib Tablets (20mg, 40mg, 60mg) is an oral multi-tyrosine kinase inhibitor targeting MET, VEGFR-1/2/3, RET, AXL, KIT, and TIE-2 on the PMBI formulary. Simultaneous inhibition of MET and AXL overcomes resistance pathways commonly triggered by VEGF-only blockade. Indicated for advanced renal cell carcinoma (RCC) following prior anti-angiogenic therapy, hepatocellular carcinoma (HCC) previously treated with sorafenib, and progressive medullary thyroid cancer.

Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.

Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.

Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.

Everolimus Tablets (0.25mg, 0.5mg, 5mg, 10mg) is an oral derivative of rapamycin that selectively inhibits the mTORC1 serine/threonine kinase complex on the WHO Model List of Essential Medicines. In oncology, mTOR inhibition halts downstream protein synthesis (p70S6K, 4E-BP1), blocking cell proliferation, nutrient sensing, and VEGF-driven angiogenesis. In organ transplantation, it suppresses lymphocyte activation. Indicated for HR+/HER2- advanced breast cancer (with exemestane), advanced renal cell carcinoma, pancreatic/gastrointestinal/lung neuroendocrine tumors (NET), subependymal giant cell astrocytoma (SEGA), and renal angiomyolipoma with tuberous sclerosis; lower doses (0.25/0.5mg) are used for kidney and liver transplant rejection prophylaxis.

Octreotide Injection (50mcg, 100mcg immediate-release; 20mg, 30mg Long-Acting Release LAR depot) is a synthetic octapeptide analogue of natural somatostatin on the WHO Model List of Essential Medicines. It binds with high affinity to somatostatin receptor subtypes sst2 and sst5, potently inhibiting the pathological hypersecretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), serotonin, gastrin, VIP, and glucagon, and causing splanchnic vasoconstriction. Indicated for symptomatic control of carcinoid syndrome (flushing, severe diarrhea), VIPomas, acromegaly, emergency management of bleeding gastroesophageal varices, and prevention of postoperative pancreatic fistula.

Octreotide Injection (50mcg, 100mcg immediate-release; 20mg, 30mg Long-Acting Release LAR depot) is a synthetic octapeptide analogue of natural somatostatin on the WHO Model List of Essential Medicines. It binds with high affinity to somatostatin receptor subtypes sst2 and sst5, potently inhibiting the pathological hypersecretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), serotonin, gastrin, VIP, and glucagon, and causing splanchnic vasoconstriction. Indicated for symptomatic control of carcinoid syndrome (flushing, severe diarrhea), VIPomas, acromegaly, emergency management of bleeding gastroesophageal varices, and prevention of postoperative pancreatic fistula.

Octreotide Injection (50mcg, 100mcg immediate-release; 20mg, 30mg Long-Acting Release LAR depot) is a synthetic octapeptide analogue of natural somatostatin on the WHO Model List of Essential Medicines. It binds with high affinity to somatostatin receptor subtypes sst2 and sst5, potently inhibiting the pathological hypersecretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), serotonin, gastrin, VIP, and glucagon, and causing splanchnic vasoconstriction. Indicated for symptomatic control of carcinoid syndrome (flushing, severe diarrhea), VIPomas, acromegaly, emergency management of bleeding gastroesophageal varices, and prevention of postoperative pancreatic fistula.

Octreotide Injection (50mcg, 100mcg immediate-release; 20mg, 30mg Long-Acting Release LAR depot) is a synthetic octapeptide analogue of natural somatostatin on the WHO Model List of Essential Medicines. It binds with high affinity to somatostatin receptor subtypes sst2 and sst5, potently inhibiting the pathological hypersecretion of growth hormone (GH), insulin-like growth factor-1 (IGF-1), serotonin, gastrin, VIP, and glucagon, and causing splanchnic vasoconstriction. Indicated for symptomatic control of carcinoid syndrome (flushing, severe diarrhea), VIPomas, acromegaly, emergency management of bleeding gastroesophageal varices, and prevention of postoperative pancreatic fistula.

Olaparib Tablets (100mg, 150mg) is a first-in-class oral poly(ADP-ribose) polymerase (PARP-1, PARP-2, PARP-3) inhibitor on the WHO Model List of Essential Medicines. It traps inactivated PARP enzymes at single-strand DNA breaks, transforming them into lethal double-strand breaks during replication. In homologous recombination deficiency (HRD) tumors (e.g., BRCA1 or BRCA2 germline or somatic mutations), cancer cells cannot repair double-strand breaks, triggering synthetic lethality and tumor apoptosis while sparing normal cells. Indicated for maintenance therapy in BRCA-mutated advanced ovarian cancer, HER2-negative metastatic breast cancer with germline BRCA mutation, metastatic pancreatic adenocarcinoma, and HRR gene-mutated metastatic castration-resistant prostate cancer.

Olaparib Tablets (100mg, 150mg) is a first-in-class oral poly(ADP-ribose) polymerase (PARP-1, PARP-2, PARP-3) inhibitor on the WHO Model List of Essential Medicines. It traps inactivated PARP enzymes at single-strand DNA breaks, transforming them into lethal double-strand breaks during replication. In homologous recombination deficiency (HRD) tumors (e.g., BRCA1 or BRCA2 germline or somatic mutations), cancer cells cannot repair double-strand breaks, triggering synthetic lethality and tumor apoptosis while sparing normal cells. Indicated for maintenance therapy in BRCA-mutated advanced ovarian cancer, HER2-negative metastatic breast cancer with germline BRCA mutation, metastatic pancreatic adenocarcinoma, and HRR gene-mutated metastatic castration-resistant prostate cancer.

Vincristine Sulfate Injection (1mg) is a natural vinca alkaloid antineoplastic on the WHO Model List of Essential Medicines. It binds specifically to tubulin dimers, preventing their polymerization into microtubules and causing mitotic spindle dissolution, arresting proliferating cells in metaphase (M phase). Indicated as an essential backbone component for acute lymphoblastic leukemia (ALL), Hodgkin and non-Hodgkin lymphomas, neuroblastoma, rhabdomyosarcoma, and Wilms tumor.

Abiraterone Acetate Tablets (250mg, 500mg) is an oral prodrug inhibitor of androgen biosynthesis on the WHO Model List of Essential Medicines. It is converted to abiraterone, which selectively and irreversibly inhibits the 17-alpha-hydroxylase and C17,20-lyase activities of the CYP17A1 enzyme in testicular, adrenal, and intratumoral prostate cancer tissues. This shuts down androgen synthesis across all three sources, depriving androgen-dependent prostate cancer cells of testosterone and DHT. Because CYP17 inhibition blocks cortisol production, secondary ACTH elevation triggers mineralocorticoid excess (hypertension, hypokalemia, edema); therefore, abiraterone MUST ALWAYS be co-administered with oral prednisone. Indicated in combination with prednisone for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).

Enzalutamide Tablets (40mg) is a second-generation non-steroidal androgen receptor inhibitor on the WHO Model List of Essential Medicines. It exerts a triple mechanism: competitive inhibition of androgen binding to androgen receptors (with 8-fold higher affinity than bicalutamide), inhibition of androgen receptor nuclear translocation, and inhibition of androgen receptor DNA binding and coactivator recruitment, inducing prostate cancer cell apoptosis without agonistic properties. Indicated for castration-resistant prostate cancer (metastatic and non-metastatic CRPC) and metastatic castration-sensitive prostate cancer (mCSPC).

Filgrastim Injection (300mcg / 30 million units per 1ml pre-filled syringe/vial) is a recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) on the WHO Model List of Essential Medicines. Produced by recombinant DNA technology in E. coli, it binds to specific cell-surface G-CSF receptors on hematopoietic progenitor cells in the bone marrow, stimulating the proliferation, differentiation, and survival of neutrophils, as well as enhancing their phagocytic and bactericidal functions. Indicated to decrease the incidence of infection (febrile neutropenia) in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs, acute myeloid leukemia post-chemotherapy, and mobilization of peripheral blood progenitor cells for stem cell transplantation.

Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine is a sterile liquid suspension of virus-like particles (VLPs) of the L1 major capsid protein on the WHO Model List of Essential Medicines. It stimulates high titers of neutralizing IgG antibodies that transudate into cervicovaginal secretions, blocking HPV entry into basal epithelial cells. Types 16 and 18 cause ~70% of cervical cancers, anal cancers, and precancerous lesions (CIN 2/3), while types 6 and 11 cause ~90% of anogenital warts (condyloma acuminata). Indicated for prevention of cervical, vulvar, vaginal, and anal cancers, precancerous dysplasias, and genital warts in females and males aged 9 through 26 (and up to 45 years).

Ibrutinib Capsules (140mg) is a first-in-class oral irreversible inhibitor of Bruton's Tyrosine Kinase (BTK) on the WHO Model List of Essential Medicines. It forms a covalent bond with cysteine 481 in the BTK active site, permanently disabling B-cell antigen receptor (BCR) signaling and halting malignant B-cell proliferation, survival, and homing to lymphatic niches. Indicated for Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL), Waldenstrom's Macroglobulinemia, and chronic Graft-versus-Host Disease (cGVHD).

Lenvatinib Capsules (4mg) is an oral receptor tyrosine kinase inhibitor that selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, along with fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3, FGFR-4), PDGFR-alpha, KIT, and RET. Indicated for locally recurrent or metastatic, progressive radioactive iodine-refractory differentiated thyroid cancer, first-line treatment of unresectable hepatocellular carcinoma (HCC), and in combination with pembrolizumab for advanced endometrial carcinoma or advanced RCC.